79 related articles for article (PubMed ID: 10560438)
1. [Liver concentration of CPT-11, SN-38 and SN-38 GLU in intraperitoneal and intravenous administration of CPT-11].
Maruyama M; Nagahama T; Yuasa Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1967-9. PubMed ID: 10560438
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
[TBL] [Abstract][Full Text] [Related]
3. [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Maruyama M; Nagahama T; Ebuchi M; Yuasa Y
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1855-7. PubMed ID: 11086429
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
Maruyama M; Toukairin Y; Baba H; Kure N; Nagahama T; Ebuchi M
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1505-7. PubMed ID: 11707965
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis.
Maruyama M; Nagahama T; Yuasa Y
Anticancer Res; 1999; 19(5B):4187-91. PubMed ID: 10628373
[TBL] [Abstract][Full Text] [Related]
6. [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].
Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1602-4. PubMed ID: 14619474
[TBL] [Abstract][Full Text] [Related]
7. [Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
Nagahama T; Maruyama M; Goseki N
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1866-9. PubMed ID: 11086432
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
Ahn BJ; Choi MK; Park YS; Lee J; Park SH; Park JO; Lim HY; Kang WK; Ko JW; Yim DS
Eur J Clin Pharmacol; 2010 Dec; 66(12):1235-45. PubMed ID: 20827550
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
Maruyama M; Toukairin Y; Baba H; Yoshida T; Kure N; Nagahama T; Ebuchi M
Gan To Kagaku Ryoho; 2000 Oct; 27(12):1858-60. PubMed ID: 11086430
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
Guichard S; Chatelut E; Lochon I; Bugat R; Mahjoubi M; Canal P
Cancer Chemother Pharmacol; 1998; 42(2):165-70. PubMed ID: 9654118
[TBL] [Abstract][Full Text] [Related]
13. [Experimental study on intraperitoneal and intravenous administration of anti-tumor agents for liver metastasis].
Maruyama M; Nagahama T; Ebuchi M; Irie T; Yoshida T; Kure M
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1782-5. PubMed ID: 10560394
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intraperitoneal irinotecan in a pig model.
Turcotte S; Sideris L; Younan R; Drolet P; Dubé P
J Surg Oncol; 2010 Jun; 101(7):637-42. PubMed ID: 20461774
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat.
Tringali G; Bettella F; Greco MC; Campisi M; Renier D; Navarra P
J Pharm Pharmacol; 2012 Mar; 64(3):360-5. PubMed ID: 22272720
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
Hribaschek A; Kuhn R; Pross M; Meyer F; Fahlke J; Ridwelski K; Boltze C; Lippert H
Surg Today; 2006; 36(1):57-62. PubMed ID: 16378195
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor activity of CPT-11 against rat Walker 256 carcinoma].
Furuta T; Yokokura T; Mutai M
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2757-60. PubMed ID: 3415271
[TBL] [Abstract][Full Text] [Related]
20. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
